Related Experiment Video

Updated: May 13, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Targeting PI3Kδ: One man's meat is another man's poison

Michaela Prchal-Murphy1, Eva Maria Putz, Michael Freissmuth

  • 1Institute of Pharmacology and Toxicology; Department for Biomedical Science; University of Veterinary Medicine Vienna; Vienna, Austria.

Oncoimmunology
|March 14, 2013
PubMed

Insights

Targeting phosphoinositide-3-kinase δ (PI3Kδ) may limit cancer therapy effectiveness. Inhibiting PI3Kδ impairs cytotoxic T lymphocytes and NK cells, potentially hindering tumor cell attacks despite direct anticancer effects.

Area of Science:

  • Immunology
  • Molecular Biology
  • Oncology

Background:

  • The enzyme phosphoinositide-3-kinase δ (PI3Kδ) plays a crucial role in cytotoxic T lymphocyte (CTL) function.
  • Targeting PI3Kδ is a potential therapeutic strategy for cancer treatment.

Purpose of the Study:

  • To investigate the role of PI3Kδ in the CTL killing pathway.
  • To evaluate the potential trade-offs of inhibiting PI3Kδ in cancer therapy.

Main Methods:

  • Analysis of the canonical killing pathway of CTLs.
  • Assessment of PI3Kδ signaling in immune cells.

Main Results:

  • PI3Kδ is essential for multiple stages of the CTL killing pathway.
  • Inhibition of PI3Kδ may lead to a balance between direct anticancer effects and impaired CTL and NK cell activity against tumors.

Conclusions:

  • While targeting PI3Kδ shows promise in oncology, its inhibition may compromise the anti-tumor immune response mediated by CTLs and NK cells.
  • The therapeutic benefits of PI3Kδ inhibition require careful consideration of its impact on immune cell function.
Keywords:
cytotoxic T lymphocytes (CTLs)natural killer (NK) cellssignal-interception based therapytumor immunosurveillance

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...